A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer

  • End date
    Jan 4, 2026
  • participants needed
  • sponsor
Updated on 4 October 2022


To evaluate the safety and tolerability of Tarlatamab and will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Condition Neuroendocrine Prostate Cancer
Treatment AMG 757, Tarlatamab
Clinical Study IdentifierNCT04702737
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Participant has provided informed consent prior to initiation of any study specific activities/procedures
Men aged ≥ 18 years at time of signing the informed consent
Metastatic de novo or treatment-emergent neuroendocrine prostate cancer (NEPC) defined by histological, immunohistochemistry, or genomic analyses of baseline tumor tissue (by local assessment) or circulating tumor DNA (ctDNA) (by local assessment) as per protocol
At least 1 line of prior systemic treatment per protocol
For participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation
Participants with treatment-emergent NEPC or de novo NEPC with histologic evidence of prostate cancer with neuroendocrine differentiation without a history of bilateral orchiectomy are required to remain on luteinizing hormone-releasing hormone (LHRH) analogue therapy during the course of protocol therapy
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 per Prostate Cancer Working Group 3 (PCWG3) modifications
Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
Participants with treated brain metastases are eligible provided they meet defined criteria
Adequate organ function as defined in protocol

Exclusion Criteria

History of other malignancy within the past 2 years, with exceptions
Malignancy treated with curative intent and with no known active disease present for ≥ 2 years before enrollment and felt to be at low risk for recurrence by the treating physician
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
Adequately treated non-muscle invasive urothelial carcinoma
History or presence of hematological malignancies unless curatively treated with no
evidence of disease ≥ 2 years
Untreated or symptomatic brain metastases and leptomeningeal disease
Anti-tumor therapy within 28 days of study day 1; concurrent use of hormone deprivation therapy for hormone refractory prostate is permitted; participants on a stable bisphosphonate or denosumab for ≥ 30 days prior to study day 1 are eligible
Participants who received conventional chemotherapy are eligible if at least 14 days
have elapsed and if all treatment-related toxicities have resolved to Grade ≤
Prior palliative radiotherapy must have been completed at least 7 days before the first dose of Tarlatamab
Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior study day 1
Participants who received androgen signaling inhibitor are eligible if at least 14 days have elapsed and if all treatment-related toxicity has been resolved to Grade ≤ 1
Active autoimmune disease requiring systemic treatment within the past 2 years
Known positive test for human immunodeficiency virus (HIV) or hepatitis
Unresolved toxicities from prior anti-tumor therapy, defined as not having resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 grade 0 or 1 (with the exception of alopecia or toxicities that are stable and well-controlled)
History of hypophysitis or pituitary dysfunction
Has evidence of interstitial lung disease or active, non-infectious pneumonitis
Participants on prior DLL3-targeted therapy may be eligible if discussed with Amgen medical monitor prior to enrollment
History or evidence of SARS-COV2 infection unless agreed upon with Medical Monitor and with no acute symptoms of COVID19 disease within 14 days prior to first dose of IP (counted from day of positive test for asymptomatic subjects)
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note